Interestingly, EGFR ligands EREG and AREG are observed to be highly upregulated in CRC and are close to being validated as a predictive dichotomized biomarker for EGFR-targeted mAb response, which will help identify patients likely to respond to EGFR-targeted mAbs independent of tumor mutational status and primary tumor location. The gene discussed is AREG; the disease is neoplasm.